Literature DB >> 28839102

The beginnings of cardiac catheterization and the resulting impact on pulmonary medicine.

John B West1.   

Abstract

The early history of cardiac catheterization has many interesting features. First, although it would be natural to assume that the procedure was initiated by cardiologists, two of the three people who shared the Nobel Prize for the discovery were pulmonologists, while the third was a urologist. The primary objective of the pulmonologists André Cournand and Dickinson Richards was to obtain mixed venous blood from the right heart so that they could use the Fick principle to calculate total pulmonary blood flow. Cournand's initial catheterization studies were prompted by his reading of an account by Werner Forssmann, who catheterized himself 12 years before. His bold experiment was one of the most bizarre in medical history. In the earliest studies that followed, Cournand and colleagues first passed catheters into the right atrium, and then into the right ventricle, and finally, the pulmonary artery. At the time, the investigators did not appreciate the significance of the low vascular pressures, nor that what they had done would revolutionize interventional cardiology. Within a year, William Dock predicted that there would be a very low blood flow at the top of the upright lung, and he proposed that this was the cause of the apical localization of pulmonary tuberculosis. The fact that the pulmonary vascular pressures are very low has many implications in lung disease. Cardiac catheterization changed the face of investigative cardiology, and its instigators were awarded the Nobel Prize in 1956.
Copyright © 2017 the American Physiological Society.

Entities:  

Keywords:  pulmonary tuberculosis; pulmonary vascular pressures; self-experimentation; uneven pulmonary blood flow

Mesh:

Year:  2017        PMID: 28839102     DOI: 10.1152/ajplung.00133.2017

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  5 in total

1.  Designing a SARS-CoV-2 T-Cell-Inducing Vaccine for High-Risk Patient Groups.

Authors:  Hans-Georg Rammensee; Cécile Gouttefangeas; Sonja Heidu; Reinhild Klein; Beate Preuß; Juliane Sarah Walz; Annika Nelde; Sebastian P Haen; Michael Reth; Jianying Yang; Ghazaleh Tabatabai; Hans Bösmüller; Helen Hoffmann; Michael Schindler; Oliver Planz; Karl-Heinz Wiesmüller; Markus W Löffler
Journal:  Vaccines (Basel)       Date:  2021-04-24

2.  Conceptualising Surgical Innovation: An Eliminativist Proposal.

Authors:  Giles Birchley; Jonathan Ives; Richard Huxtable; Jane Blazeby
Journal:  Health Care Anal       Date:  2020-03

3.  A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer.

Authors:  Hans-Georg Rammensee; Karl-Heinz Wiesmüller; P Anoop Chandran; Henning Zelba; Elisa Rusch; Cécile Gouttefangeas; Daniel J Kowalewski; Moreno Di Marco; Sebastian P Haen; Juliane S Walz; Yamel Cardona Gloria; Johanna Bödder; Jill-Marie Schertel; Antje Tunger; Luise Müller; Maximilian Kießler; Rebekka Wehner; Marc Schmitz; Meike Jakobi; Nicole Schneiderhan-Marra; Reinhild Klein; Karoline Laske; Kerstin Artzner; Linus Backert; Heiko Schuster; Johannes Schwenck; Alexander N R Weber; Bernd J Pichler; Manfred Kneilling; Christian la Fougère; Stephan Forchhammer; Gisela Metzler; Jürgen Bauer; Benjamin Weide; Wilfried Schippert; Stefan Stevanović; Markus W Löffler
Journal:  J Immunother Cancer       Date:  2019-11-15       Impact factor: 13.751

Review 4.  In-Vivo Microsystems: A Review.

Authors:  Paddy French
Journal:  Sensors (Basel)       Date:  2020-09-01       Impact factor: 3.576

Review 5.  The changing face of pulmonary hypertension diagnosis: a historical perspective on the influence of diagnostics and biomarkers.

Authors:  Jenny L Hewes; Ji Young Lee; Karen A Fagan; Natalie N Bauer
Journal:  Pulm Circ       Date:  2020-02-04       Impact factor: 3.017

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.